Pure Biologics
Pure Biologics S.A. is a Polish clinical-stage biopharmaceutical company developing novel immuno-oncology antibody therapeutics (PB004/PBA-0405 and PB003G/PBA-0111) for licensing and co-development with pharmaceutical partners, listed on the Warsaw Stock Exchange (PURE).
- Company typePublic
- Founded2010
- HeadquartersWrocław, Poland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pure Biologics does
Pure Biologics S.A. is a clinical-stage Polish biopharmaceutical company founded in 2010 and headquartered in Wrocław, Poland, that develops novel (non-generic, non-biosimilar) biological drugs based on proprietary antibody and aptamer technology platforms for immuno-oncology applications. The company's therapeutic portfolio centers on two pipeline candidates: PB004 (PBA-0405), an affucosylated IgG1 antibody targeting the ROR-1 tumor antigen to drive antibody-dependent cellular cytotoxicity (ADCC) in solid tumors and hematologic malignancies, and PB003G (PBA-0111), a dual-action anti-GARP antibody designed to simultaneously deplete immunosuppressive regulatory T cells in the tumor microenvironment and stimulate cytotoxic NK and T cells. Both candidates are progressing through Phase 0 clinical trials in US sites following FDA approvals secured in December 2023 and July 2024, respectively, with Phase 1 funding for PB004 covered by a PLN 32 million non-dilutive grant from the Polish Medical Research Agency.
The company is publicly listed on the Main Market of the Warsaw Stock Exchange under ticker PURE (ISIN: PLPRBLG00010), having transferred from NewConnect in 2020, with 12,244,716 shares outstanding and co-founder Dr. Filip Jelen serving as CEO alongside CSO Dr. Pieter Spee. Revenue mechanics today are dominated by contract research services for pharmaceutical clients and milestone-based recognition of non-dilutive grants, with FY 2025 revenue of PLN 985,000 (~$250K equivalent) versus PLN 3.3 million in FY 2024. The forward business model is built around signing co-development partnership agreements that transfer downstream development costs to pharmaceutical partners; the company has announced a partnership agreement covering both PB004 and PB003G, with future licensing/royalty upside contingent on Phase 1 progression.
Recent corporate actions signal an active strategic repositioning: under a May 14, 2026 EGM, the company has proposed issuing Series Q, R, and S shares alongside a rebrand to MultiQure S.A., suggesting intent to scale into a multi-asset platform rather than remain a single-indication biotech. The 22-person team is small by clinical-stage biotech standards and reflects an asset-light, partnering-oriented operating model rather than in-house commercial buildout.
Pure Biologics firmographics
Firmographics- Name
- Pure Biologics
- Legal name
- Pure Biologics S.A.
- Website
- https://purebiologics.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pure Biologics S.A. is a Polish clinical-stage biopharmaceutical company developing novel immuno-oncology antibody therapeutics (PB004/PBA-0405 and PB003G/PBA-0111) for licensing and co-development with pharmaceutical partners, listed on the Warsaw Stock Exchange (PURE).
- Ownership category
- akta.pro rank
Pure Biologics industry classification
Industry- Product category
- Immuno-oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Bispecific & Multispecific Antibodies (HLAAAAAF), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where Pure Biologics is headquartered
LocationHeadquarters
- HQ city
- Wrocław
- HQ country
- Poland
- HQ region
- Europe
Offices1 record
Markets served
Pure Biologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Others
Revenue model
- Contract Research Services: Revenue generated from contracted research delivered for pharmaceutical and biotechnology companies
- Grant Funding: Non-dilutive funding from European Union and Medical Research Agency grants supporting therapeutic portfolio development
- Future Partnering/Co-development: Planned revenue from partnership agreements in co-development model where development costs are transferred to pharmaceutical partners
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Pure Biologics product offering
Product offeringCore offering
Pure Biologics is a clinical-stage biopharmaceutical company that discovers and develops novel biological drugs (therapeutic antibodies and aptamers) for immuno-oncology applications. Its pipeline includes PB004 (PBA-0405), an affucosylated IgG1 antibody targeting ROR-1 for solid tumors and hematological malignancies, and PB003G (PBA-0111), a dual-action antibody modulating the tumor microenvironment. The company operates on a partnership-based commercialization model, transferring later-stage development and commercialization to large pharmaceutical partners.
Product overview
Pure Biologics is a Polish biopharmaceutical company developing novel therapeutic molecules based on antibodies and aptamers for immuno-oncology applications. The company's portfolio includes two clinical-stage pipeline candidates: PB004 (PBA-0405), an affucosylated IgG1 antibody targeting ROR-1 for solid tumors and hematological malignancies; and PB003G (PBA-0111), a dual-action antibody targeting immunosuppressive Treg cells and stimulating cytotoxic immune response. The company operates a proprietary antibody technology platform and was the first entity in Poland to focus on developing completely new biological drugs (not generic or biosimilar). Pure Biologics is publicly traded on the Warsaw Stock Exchange (PURE).
Differentiator
Problem solved
Functional benefit
Products and services
- PB004 (PBA-0405)
- PB003G (PBA-0111)
Quantifiable outcome
- Phase 0 clinical trials completed/progressing in US for PB004 (PBA-0405) and PB003G (PBA-0111) molecules
- +1 more outcomes
Companies that use Pure Biologics
Customer profileSegments2 records
Ideal customer profiles1 record
Pure Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Pure Biologics partnerships and signals
Strategic signalScale indicators4 records
Recent moves8 records
Expansion highlights5 records
Pure Biologics competitors and assessment
Company assessmentDirect peers
- CytomX Therapeutics: Clinical-stage biotech using proprietary antibody engineering platforms (Probody) to develop conditional immuno-oncology therapeutics; directly comparable as a platform-based antibody oncology developer.
- MacroGenics: Develops bispecific antibodies and antibody-based immuno-oncology therapeutics; directly comparable to Pure Biologics' dual-action antibody (PB003G) and broader immuno-oncology focus.
- Molecular Partners: Swiss clinical-stage biotech developing non-antibody biologic scaffolds (DARPins) for oncology; comparable as a Europe-based, novel-protein-therapeutics developer with partnership-driven business model.
- Celldex Therapeutics: Clinical-stage biotech developing antibody-based immuno-oncology therapeutics; comparable in size, stage, and antibody-platform approach to Pure Biologics' lead programs.
- Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing bispecific immune-stimulating antibody conjugates; closely comparable in stage, mechanism (bispecific immune agonism), and partnership model.
Broad incumbents
- Genmab: Global antibody therapeutics leader with multiple approved products (incl. bispecifics like glofitamab) and proprietary DuoBody/IHex platforms; highly comparable antibody-engineering and immuno-oncology focus, though vastly larger and commercial-stage.
- MorphoSys: Major antibody therapeutics company with proprietary antibody libraries and a pipeline of bispecific and immuno-oncology candidates; comparable antibody-discovery platform approach at a much larger scale.
- Innate Pharma: Established European clinical-stage immuno-oncology company developing antibody-based therapeutics engaging innate immunity; comparable therapeutic focus and European base, though larger and more diversified.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Pure Biologics social profiles
Digital presencePure Biologics compliance and trust
Trust signalCompliance1 record
Pure Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pure Biologics leadership team
Management profileNumber of profiles
Profiles3 records
Pure Biologics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pure Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pure Biologics
What does Pure Biologics do?
Pure Biologics is a clinical-stage biopharmaceutical company that discovers and develops novel biological drugs (therapeutic antibodies and aptamers) for immuno-oncology applications. Its pipeline includes PB004 (PBA-0405), an affucosylated IgG1 antibody targeting ROR-1 for solid tumors and hematological malignancies, and PB003G (PBA-0111), a dual-action antibody modulating the tumor microenvironment. The company operates on a partnership-based commercialization model, transferring later-stage development and commercialization to large pharmaceutical partners.
Is Pure Biologics a public or private company?
Pure Biologics is a public company. It is classified as public and is currently operating.
When was Pure Biologics founded?
Pure Biologics was founded in 2010. It employs 11 to 50 people.
Where is Pure Biologics based?
Pure Biologics is headquartered in Wrocław, Poland, in the Europe region.
How does Pure Biologics make money?
Three revenue lines are on record. Contract Research Services are the primary driver. The others are grant Funding and future Partnering/Co-development.
Who are Pure Biologics's main competitors?
Direct peers on record are CytomX Therapeutics, MacroGenics, Molecular Partners, Celldex Therapeutics and Bolt Biotherapeutics. Broad incumbents are Genmab, MorphoSys and Innate Pharma.
Does Pure Biologics have an API?
No public API is recorded for Pure Biologics.
What industry is Pure Biologics in?
Pure Biologics's product category is Immuno-oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.